of the Sigma-Aldrich group (Nasdaq: SIAL), is pleased to announce it has
acquired 2,000 sq. meters of office space in the heart of the Genopole(R)
d'Evry biopark in the region of Paris. The official inauguration will take
place on October 19 at 11:30 a.m.
Sigma-Proligo provides researchers throughout the world with
high-quality oligonucleotides due to a high throughput synthesis platform,
enabling it to deliver high-quality products at short deadlines.
With 65 employees in France, the majority of whom are researchers,
Sigma- Proligo has world-class expertise in nucleic acid synthesis and
holds several key patents in siRNA gene silencing technology. Thanks to an
R&D team, which is also based in Evry, this site is expected to become a
center of excellence within the Sigma-Aldrich group. The new facility is
expected to provide the capacity needed for the Company to advance the
production of high-quality oligonucleotides in order to meet emerging needs
within the bioscience research sector.
Sigma-Proligo has extensive knowledge in the fields of DNA synthesis,
siRNA, long amino oligos, quantitative PCR probes and specialized products
such as Locked Nucleic Acid (LNA). Sigma-Proligo develops new protocols and
new methods in the field of oligonucleotides, and is one of four companies
with the MIT license on siRNAs.
"The 'biotech' image of Genopole, as well as the offices and working
environment perfectly adapted to our operations, have been the main reasons
behind our expansion into Evry," said Khalil Arar, operations manager of
Sigma-Aldrich Evry. "The RNAi market has a predicted compound annual growth
rate of 14%, and these new facilities are expected to provide Sigma-Proligo
with the capacity to meet the increasing market demand for RNAi products.
The facilities should also enable the Company to continue to supply
customers with innovative products."
Thierry Mandon, President of Genopole, said, "A mature company moving
onto the campus boosts the attractiveness of Evry-Corbeil as a business
location, and demonstrates its credibility in the biotech sector."
Pierre Tambourin, CEO of Genopole, added "This move will promote
interactivity with our start-ups, which will profit from Sigma Proligo's
knowledge, and our larger companies who need dynamic local links in order
to pursue their development."
Marc Rebois, Director of SEM Genopole, the company that creates and
manages the site's real estate and business accommodation resources, added,
"Welcoming such a well-known company to Evry-Corbeil is a reward for our
ongoing focus on truly biotech-dedicated real estate solutions, and it also
constitutes recognition of our campus on the international level." About Sigma-Aldrich:
Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits
are used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in
pharmaceutical and other high technology manufacturing. The Company has
customers in life science companies, university and government
institutions, hospitals, and in industry. Over one million scientists and
technologists use its products. Sigma-Aldrich operates in 35 countries and
has 7,200 employees providing excellent service worldwide. Sigma-Aldrich is
committed to Accelerating Customer Success through Leadership in Life
Science, High Technology and Service. For more information about
Sigma-Aldrich, please visit its award- winning Web site at
About Genopole(R): The first French biopark dedicated to genetic
research and biotechnologies, Genopole brings together a 90, 000 square
meter site for private and public research laboratories, biotechnological
companies as well as university training (Evry Val d'Essonne University).
With 23 research laboratories on the campus and a portfolio of over 60
biotechnologies companies, innovation for therapeutical purposes is right
at the heart of the concerns at Genopole. Their aim is to foster the
development of research into genomics, post-genomics and associated
sciences and to transfer technologies to the industrial sector, developing
high-level information in these fields and creating and supporting
biotechnology companies. Visit its Web Site at http://www.genopole.fr . [标签:content1][标签:content2]
作者:admin@医学,生命科学 2011-08-24 17:20